Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis
Michael Schwarz
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorBehrang Mozayani
Department of Pathology, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorMichael Trauner
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
Albert Friedrich Stättermayer
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Correspondence
Albert Friedrich Stättermayer, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Austria.
Email: [email protected]
Search for more papers by this authorMichael Schwarz
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorBehrang Mozayani
Department of Pathology, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorMichael Trauner
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
Albert Friedrich Stättermayer
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Correspondence
Albert Friedrich Stättermayer, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Austria.
Email: [email protected]
Search for more papers by this author
Supporting Information
| Filename | Description |
|---|---|
| bjh19892-sup-0001-FigureS1.docxWord 2007 document , 335.2 KB |
Figure S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017; 3(1):17086.
- 2Guerra J, Kampa KC, Morsoletto DGB, Junior AP, Ivantes CAP. Hepatitis E: a literature review. J Clin Transl Hepatol. 2017; 5(4): 376–383.
- 3Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, et al. The global burden of hepatitis E outbreaks: a systematic review. Liver Int. 2017; 37(1): 19–31.
- 4Aspinall EJ, Couturier E, Faber M, Said B, Ijaz S, Tavoschi L, et al. Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015. Euro Surveill. 2017; 22(26):30561.
- 5Cangin C, Focht B, Harris R, Strunk JA. Hepatitis E seroprevalence in the United States: results for immunoglobulins IgG and IgM. J Med Virol. 2019; 91(1): 124–131.
- 6Gérolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med. 2008; 358(8): 859–860.
- 7Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009; 361(10): 1025–1027.
- 8Ollier L, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009; 150(6): 430–431.
- 9Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015; 372(10): 914–922.
- 10June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382): 1361–1365.
- 11de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022; 76(4): 959–974.
- 12 European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018; 68(6): 1256–1271.
- 13De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000; 31(4): 997–1004.
- 14Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E virus infection in cancer patients. Transplant Cell Ther. 2022; 28(11): 788.e1–788.e5.
- 15Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32(1): 34–48.
Citing Literature
